Base de dados : IBECS
Pesquisa : D12.776.124.486.485.114.071 [Categoria DeCs]
Referências encontradas : 21 [refinar]
Mostrando: 1 .. 10   no formato [Longo]

página 1 de 3 ir para página          

  1 / 21 IBECS  
              next record last record
seleciona
para imprimir
Fotocópia
Id: 172941
Autor: Ozkars, MY; Keskin, O; Tokur, M; Ulasli, M; Gogebakan, B; Ciralik, H; Kucukosmanoglu, E; Demirel, C; Oztuzcu, S; Kahraman, H.
Título: Comparing the effects of fluticasone, anti-IgE and anti-TNF treatments in a chronic asthma model
Fonte: Allergol. immunopatol;46(3):226-234, mayo-jun. 2018. tab, graf.
Idioma: en.
Resumo: Background: Corticosteroids are used in the treatment of asthma. The aim of this study was to determine the efficacy of anti-IgE and anti-TNF alpha as asthma treatments. Methods: A mouse model of chronic asthma was developed. The fluticasone group was exposed to fluticasone and the anti-IgE and anti-TNF groups were administered anti-IgE or anti-TNF. IL-4, and IgE levels were measured, and histological analysis, pathological analysis and miRNA-126, miRNA-133a analyses were applied. Results: The cell concentration in the BAL fluid decreased in all the treatment groups. The rate of perivascular and peribronchial cell infiltration decreased in the lung in the high-dose anti-IgE and anti-TNF groups. Smooth muscle thickness decreased in the lung tissue in the low-dose anti-IgE and anti-TNF groups. Bronchial wall thickness decreased in the lung tissue in the fluticasone+anti-IgE group. The IL-4 level in BAL fluid decreased in the high-dose anti-IgE, fluticasone+anti-IgE and anti-TNF groups. IgE levels increased in the BAL fluid in the high-dose anti-IgE and anti-TNF groups. The lymphocyte level increased in the BAL fluid in the high-dose anti-IgE group. The macrophage level decreased in the BAL fluid in the anti-TNF group. The relative expression of miRNA-126 increased in all groups. The relative expression of miRNA-133a decreased in the placebo and fluticasone groups. The relative expression of miRNA-133a increased in the low-dose anti-IgE, high-dose anti-IgE, fluticasone+anti-IgE and anti-TNF groups. Conclusions: The results showed that anti-IgE is successful as a treatment. Fluticasone+anti-IgE and anti-TNF were seen to be superior to other therapeutic modalities when used for prophylaxis (AU)

No disponible
Responsável: ES1.1
BNCS


  2 / 21 IBECS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: 145883
Autor: Bosque García, M.
Título: Experiencia pediátrica en el tratamiento del asma grave con anticuerpos anti IgE (omalizumab) / No disponible
Fonte: An. pediatr. (2003. Ed. impr.);72(supl.esp.1):1-3, mayo 2010. ilus, tab.
Idioma: es.
Resumo: No disponible

No disponible
Responsável: ES1.1
BNCS


  3 / 21 IBECS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: 139368
Autor: Torabi Sagvand, B; Mirminachi, B; Abolhassani, H; Shokouhfar, T; Keihanian, T; Amirzargar, A; Mahdaviani, A; Aghamohammadi, A.
Título: IgG anti-IgA antibodies in paediatric antibody-deficient patients receiving intravenous immunoglobulin
Fonte: Allergol. immunopatol;43(4):403-408, jul.-ago. 2015. tab, graf.
Idioma: en.
Resumo: Background: Immunoglobulin replacement therapy is an effective route of management for both infections and non-infectious complications in predominantly antibody deficiency (PAD). Trace levels of IgA (ranged from 0.4 to 2500 mg/ml), which exist in all immunoglobulin products, could lead to an increased susceptibility for adverse reactions in PAD patients. Furthermore, the exact mechanism which stimulates the anti-IgA antibody production in PAD is still unknown. The aim of this study was to evaluate IgG anti-IgA antibodies in PAD patients receiving intravenous immunoglobulin (IVIg) and its predisposing factors. Methods: Available patients with confirmed diagnosis of PAD, who underwent regular IVIg replacement therapy in our centre, were enrolled in the study. Control group included 24 healthy individuals as the negative control and eight symptomatic patients with IgA deficiency as the positive control groups. IgG anti-IgA antibodies level was measured by the ELISA method. Results: A significant difference was observed between Anti-IgA level of common variable immunodeficiency (CVID) and other PAD groups (p = 0.02). Moreover, six CVID patients were seropositive for the IgG anti-IgA antibody, with higher susceptibility to the adverse reactions (p < 0.001). IgG anti-IgA level has a negative relationship with serum IgA level (r = −0.06) and IVIg treatment duration (r = −0.006). Conclusion: Our data suggested that there was a significant association between anti-IgA antibody presence and the adverse reactions, especially in CVID patients with higher susceptibility to produce this constitutional antibody (AU)

No disponible
Responsável: ES1.1
BNCS


  4 / 21 IBECS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: 128301
Autor: Puig, L; Sáez, E; Lozano, M. J; Bordas, X; Carrascosa, J. M; Gallardo, F; Luelmo, J; Sánchez-Regaña, M; Alsina, M; García-Patos, V.
Título: Reacciones a la infusión de infliximab en pacientes dermatológicos / Reactions to Infliximab Infusions in Dermatologic Patients: Consensus Statement and Treatment Protocol
Fonte: Actas dermo-sifiliogr. (Ed. impr.);100(2):103-112, mar. 2009. tab.
Idioma: es.
Resumo: Infliximab, un anticuerpo monoclonal quimérico que se une y bloquea al factor de necrosis tumoral alfa, constituye el agente biológico más eficaz aprobado para el tratamiento de la psoriasis moderada a grave y se administra mediante infusión intravenosa, generalmente en Hospitales de Día de forma ambulatoria. Las reacciones infusionales, que pueden ser agudas y retardadas, constituyen el principal problema en la administración rutinaria de este fármaco, y están relacionadas con la inmunogenicidad del anticuerpo monoclonal que da lugar a la producción de anticuerpos dirigidos contra el mismo. Las reacciones infusionales a infliximab son en la mayoría de los casos no anafilácticas (mediadas por inmunoglobulina E [IgE]), lo que no excluye el retratamiento de los pacientes empleando protocolos específicos de prevención y tratamiento de las mismas. Existe una amplia experiencia sobre el uso de este fármaco en pacientes con enfermedades reumatológicas y enfermedad inflamatoria idiopática intestinal, lo que ha permitido desarrollar protocolos de tratamiento de las reacciones a la infusión aplicables a los pacientes dermatológicos, que constituyen un grupo cada vez más numeroso de los que son tratados con agentes biológicos por vía intravenosa. El objeto de la presente revisión es desarrollar un protocolo de tratamiento consensuado de las reacciones a la infusión en pacientes dermatológicos tratados con infliximab (AU)

Infliximab is a chimeric monoclonal antibody that binds to and blocks tumor necrosis factor α and is the most effective biologic agent approved for the treatment of moderate-to-severe psoriasis. It is administered by intravenous infusion, usually in day hospitals on an outpatient basis. The main problem with the administration of infliximab is the possibility of infusion reactions, which may be immediate or delayed; these reactions are related to the immunogenicity of this monoclonal antibody, leading to the production of anti-infliximab antibodies. Infusion reactions to infliximab are not usually anaphylactic (ie, they are not mediated by immunoglobulin E), and re-exposure of the patient using specific protocols to prevent and treat these reactions is therefore possible. The extensive experience in the use of infliximab for the treatment of rheumatic conditions and chronic inflammatory bowel disease has made it possible to develop infusion reaction management protocols; these can be applied to dermatologic patients, who constitute a growing proportion of patients treated with intravenous biologic agents. The aim of this review is to draw up a consensus protocol for the treatment of infusion reactions in dermatologic patients treated with infliximab (AU)
Responsável: ES1.1
BNCS


  5 / 21 IBECS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: 127479
Autor: Ye, L; Li, X; Sun, S; Guan, S; Wang, M; Guan, X; Lee, K. H; Wei, J; Liu, B.
Título: A study of circulating anti-CD25 antibodies in non-small cell lung cancer
Fonte: Clin. transl. oncol. (Print);15(8):633-637, ago. 2013. tab, ilus.
Idioma: en.
Resumo: PURPOSE: Tumors can trigger specific immune response to tumor-associated antigens but the precise mechanism remains unclear. Since regulatory T-lymphocytes (Treg) play a crucial role in controlling autoimmune responses, the present work was undertaken to test whether dysfunction of Treg cells could be involved in developing autoimmunity in patients with lung cancer. METHODS: In this study, we developed an in-house enzyme-linked immunosorbent assay to test circulating anti-CD25 autoantibodies among 272 patients with non-small cell lung cancer (NSCLC) and 226 control subjects matched in age, gender and smoking history. RESULTS: Mann-Whitney U test showed that the anti-CD25 IgG level was significantly higher in patients with NSCLC than control subjects (Z = -7.48, P < 0.001) while the anti-CD25 IgA level was not significantly changed in the patient group as compared with the control group (Z = -1.34, P = 0.181). Spearman correlation analysis failed to reveal a significant correlation between the levels of anti-CD25 IgG and IgA either in patients with NSCLC (r = -0.034, P = 0.578) or in control subjects (r = 0.055, P = 0.429). ROC analysis showed an AUC of 0.70 for anti-CD25 IgG, in which NSCLC at stage III had the highest AUC (0.75). The sensitivity against a specificity of >90 % was 35.0 % for anti-CD25 IgG assay with an inter-assay deviation of 9.4 %, and 4.0 % for anti-CD25 IgA assay with an inter-assay deviation of 13.0 %. CONCLUSIONS: Circulating anti-CD25 IgG antibody may be a useful biomarker for prognosis of lung cancer (AU)
Responsável: ES1.1
BNCS


  6 / 21 IBECS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: 101715
Autor: Pérez López, C; Nóvoa Gómez, G; Pérez Cid Rebolledad, J; Martinón Sanchez, F; Vázquez Rodríguez, M.
Título: Tiroiditis linfocitaria crónica (Hashimoto) en la población infantil de nuestro medio. Pautas de diagnóstico y de evolución / Chronic lymphocytic thyroiditis (Hashimoto) in the child population of our setting. Diagnostic guidelines and evolution
Fonte: Rev. esp. ped. (Ed. impr.);67(5):257-260, sept.-oct. 2011. ilus, tab.
Idioma: es.
Resumo: Objetivo. Reducir la exposición a los radioisótopos en la población infantil con sospecha de padecer tiroiditis de Hashimoto. Disminución de gastos económicos innecesarios. Material y métodos. Realizamos. La tiroiditis linfocitaria crónica es, en la población infantil de nuestro medio, la afección más frecuente de la glándula tiroidea; la encontramos en niñas (89%) con edad superior a 5 años. Hallamos una especificidad diagnóstica del 96% para los anticuerpos antiperoxidasas (anti-TPO), del 77% para los anticuerpos antitiroglobulina (anti-TGB), del 71% para la ecografía y del 11% para la gammagrafía. El seguimiento de estos pacientes ha sido clínico, analítico y ecográfico. Solo de forma excepcional se recurrió a la gammagrafía (10%). Conclusiones. La historia clínica junto con la exploración física, la analítica y la ecografía presentan un alto valor diagnóstico en la tiroiditis de Hashimoto, que alcanza un 96%, 84% y 71%, respectivamente. La falta de especificidad (11%) de la gammagrafía y la utilización de trazadores radioactivos desaconsejan la indicación y su uso de forma rutinaria (AU)

Objective. Reduce exposure to radioisotopes in children suspected of suffering from Hashimoto thyroiditis (chronic autoinmune thyroiditis). Decrease unnecessary costs. Patients and methods We have made a retrospective study of 56 patients with Hashimoto thyroiditis. The diagnosis was based on physical examination (goiter), laboratory data (antithyroid antibodies, thyroid stimulating hormone (TSH) and thyroid hormones), thyroid ultrasound and scintigraphy. Results. In our country, chronic autoimmune thyroiditis in child is the most common disease of the thyroid gland and it is found in girls (89%) older than 5 years. Diagnostic specificity was 96% for peroxidase antibodies (anti-TPO), 77% for thyroglobulin antibodies (anti-TGB), 71% for sonography and 11% for scintigraphy. The monitoring of these patients has been clinical, laboratory and ultrasound. Thyroid scan was usually not required to diagnose this condition (10%). Conclusions. The clinical history with physical examination, laboratory test and ultrasound have a high diagnostic value in Hashimoto thyroiditis (96%, 84% and 71% respectively). The low specificity (11%) and use of radioactive tracers in the thyroid scan, advise against routinely display (AU)
Responsável: ES1.1
BNCS


  7 / 21 IBECS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: 054681
Autor: Criado, G.
Título: TGN1412: Superagonist Dr. Jekyll and Superantigen Mr. Hyde
Fonte: Inmunología (1987);25(2):147-150, abr.-jun. 2006. ilus.
Idioma: En.
Resumo: Los anticuerpos anti-CD28 superagonistas inducen activación de los linfocitos T en ausencia de estimulación del TCR. Los ensayos clínicos de uno de tales anticuerpos, TGN1412, han resultado en severas complicaciones en los voluntarios que lo recibieron. El análisis de las características y modo de acción de los superagonistas de CD28 sugiere que dichos efectos son similares a los previamente observados con el uso terapeútico de anticuerpos anti-CD3 y al síndrome tóxico inducido por superantígenos bacterianos

Superagonistic anti-CD28 antibodies induce T cell activation in the absence of TCR triggering. Clinical trials of one of such antibodies, TGN1412, resulted in severe adverse effects in the volunteers receiving the drug. Analysis of characteristics and mechanism of action suggests that those effects are similar to those previously reported for the therapeutic use of anti-CD3 antibodies and the toxic shock syndrome triggered by bacterial superantigens
Responsável: ES1.1
ES1.1 - BNCS


  8 / 21 IBECS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: 044402
Autor: Barrachina Barberá, L; Pérez Martínez, A; León García, S; Pronzato Cuello, F; Martín Arenós, J. M; Toornador, E.
Título: Neutropenia cíclica con anticuerpos antigranulocitarios NA2 y tratamiento con factor estimulante de colonias granulocíticas recombinante / Cyclic neutropenia with anti-NA2 antibodies and treatment with recombinant granulocyte colony-stimulating factor
Fonte: An. pediatr. (2003. Ed. impr.);63(2):180-182, ago. 2005.
Idioma: Es.
Responsável: ES1.1
ES1.1 - BNCS


  9 / 21 IBECS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: 36913
Autor: García García, M. A; Rosero Arenas, M. A; Ábalos García, A; Talavera Peregrina, M; Arguedas Cervera, J; Torres Tortajada, J.
Título: Anemia hemolítica en relación con una dehiscencia de prótesis mitral biológica / Hemolytic anemia related to a dehiscence of biological mitral prosthesis
Fonte: Med. intensiva (Madr., Ed. impr.);28(9):470-476, dic. 2004. ilus, tab.
Idioma: Es.
Resumo: Se describe el caso de un paciente con una valvulopatía mitral y aórtica que desarrolla una anemia hemolítica grave junto a una angina inestable. Inicialmente se atribuyó la anemia a un mecanismo autoinmune y se probaron distintos tratamientos con escasa respuesta clínica. La hemólisis finalmente desapareció tras la corrección quirúrgica de la valvulopatía. Hacemos una revisión de la literatura sobre la asociación entre anemia hemolítica y prótesis valvulares, los hallazgos ecocardiográficos en las situaciones de hemólisis importante y el tratamiento de estos casos (AU)
Responsável: ES1.1
ES1.1 - BNCS


  10 / 21 IBECS  
              first record previous record
seleciona
para imprimir
Fotocópia
Id: 4764
Autor: Dalmau, J.
Título: Síndromes neurológicos paraneoplásicos: desde el diagnóstico de exclusión a la utilización de marcadores inmunológicos y moleculares / Paraneoplastic neurological syndromes: from the diagnosis of exclusion to the use of inmunological and molecular markers
Fonte: Neurología (Barc., Ed. impr.);15(3):114-126, mar. 2000.
Idioma: Es.
Resumo: Durante años los síndromes neurológicos paraneoplásicos se han identificado mediante la exclusión de otras complicaciones neurológicas en pacientes con cáncer. El descubrimiento de que muchos de estos síndromes se asocian a mecanismos inmunológicos permite una definición más específica e inclusiva, y facilita su diagnóstico precoz mediante la detección serológica de anticuerpos antineuronales. En un número considerable de síndromes los genes que codifican a los antígenos onconeuronales han sido clonados y su función ha empezado a conocerse. En este trabajo se revisan los mecanismos fisiopatológicos de los síndromes neurológicos paraneoplásicos y se consideran las preguntas más frecuentes respecto a su diagnóstico y tratamiento. (AU)
Responsável: ES1.1
ES1.1 - BNCS



página 1 de 3 ir para página          
   


Refinar a pesquisa
  Base de dados : Formulário avançado   
Pesquisar por : Formulário livre    Formulário básico

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde